Skip to Content
Merck
CN

Y0001511

Glibenclamide for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Glybenclamide, 5-Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide, Glyburide, N-p-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonyl-N′-cyclohexylurea

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C23H28ClN3O5S
CAS Number:
10238-21-8
Molecular Weight:
494.00
NACRES:
NA.24
PubChem Substance ID:
329831466
UNSPSC Code:
41116107
MDL number:
MFCD00056625

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Glibenclamide for peak identification, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)

SMILES string

COc1ccc(Cl)cc1C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3

InChI key

ZNNLBTZKUZBEKO-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

glibenclamide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Glibenclamide for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

hcodes

H413

Hazard Classifications

Aquatic Chronic 4

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J F Caro
The American journal of medicine, 89(2A), 17S-25S (1990-08-20)
Increased hepatic glucose production is responsible for fasting hyperglycemia in type II diabetes. Insulin resistance is the key in this process because of the inability of insulin to suppress hepatic glucose production, thereby allowing an unopposed glucagon effect. Glyburide, one
J P van Basten et al.
The Netherlands journal of medicine, 40(5-6), 305-307 (1992-06-01)
As sulphonylurea derivatives are used ubiquitously, the possibility that they may cause liver disease deserves attention. In contrast to the known pattern of reversible parenchymal liver disease due to sulphonylurea derivatives, we describe a fatal case of glyburide-induced cholestatic hepatitis
Sherrie L Aspinall et al.
The American journal of geriatric pharmacotherapy, 9(1), 58-68 (2011-04-05)
The objectives of this study were to describe changes in glyburide prescribing in cohorts that were and were not targeted by a risk reduction project, assess factors associated with glyburide discontinuation, and evaluate changes in glycated hemoglobin (ie, HbA(1c)) levels
Thomas R Moore
Diabetes care, 30 Suppl 2, S209-S213 (2008-02-27)
The clinical experience with glyburide treatment of GDM has moved ahead of the science. A single randomized controlled trial of glyburide versus insulin indicates that glyburide treatment can provide a relatively safe alternative to insulin therapy. Subsequent retrospective trials have
Faiyaz Shakeel et al.
Pharmaceutical development and technology, 19(6), 702-707 (2013-08-13)
Temperature-dependent solubility data of glibenclamide (GBN) in various ethanol-water mixtures is not reported in literature so far. Therefore, the aim of this study was to determine the mole fraction solubility of GBN in various ethanol-water mixtures at the temperature range
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service